Royal Philips to Pay $62 Million to Settle China Bribery Probe

Royal Philips, a Dutch medical supply company, has agreed to pay $62 million to resolve claims by regulators that it violated a U.S. antibribery law by improperly manipulating Chinese procurement processes and influencing public officials at Chinese state-run hospitals.

The Amsterdam-based company’s conduct in China violated the Foreign Corrupt Practices Act, the U.S. Securities and Exchange Commission said Thursday. The regulator said Philips had agreed to settle its claims without admitting to or denying the findings from its investigation.